News >

Biosimilar Filgrastim Safety Confirmed in Analysis

Jason Harris
Published: Tuesday, Mar 27, 2018

Dr Nadia Harbeck

Nadia Harbeck, MD, PhD
EP2006 (Zarxio; biosimilar filgrastim-sndz), a filgrastim (Neupogen) biosimilar, produced safety results equivalent to those observed with referent filgrastim in a combined analysis of 2 phase III breast cancer studies from the United States and Europe.

Mean duration of severe neutropenia (primary endpoint) was 1.04 (±1.51) days in cycle 1. The mean absolute neutrophil count (ANC) time course showed the expected increase at day 3 and subsequent decrease with nadir at days 7 to 8, with recovery from day 10.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication
x